This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print this page

Life Sciences Research & Development

Adapting R&D to the new Life Sciences ecosystem


Deloitte’s Life Sciences R&D practice is comprised of experienced practitioners who understand the unique challenges that are confronting today’s R&D organizations; hence our approaches are pragmatic and realistic. Our focus is on helping clients in their efforts to transform the value R&D brings to the life science marketplace.

Learn more about Life Sciences Research & Development by clicking on the tabs below:
  • Here's the debate
  • My take
  • Join the conversation

Mini case-study:

Redefining a research operating strategy
Client issue:
Our client, a major pharmaceutical company, pursued a strategy of driving greater New Molecular Entity (NME) approvals through increased R&D spending. While this approach led to early-stage pipeline growth, it did not translate to late-stage clinical success and with increasing R&D costs and lower revenues, the strategy was not sustainable. Our client recognized that the current research operating model had to change if it was to drive productivity up in the increasingly constrained environment.
Specific challenges to address included:

  • Fragmented research network
  • Inefficient resource allocation
  • Missed opportunities
  • Inflexible cost structure
  • No clear talent management strategy

How we helped
A senior team of life sciences practitioners conducted a current state assessment resulting in a pipeline flow analysis to understand the long-term demand for resources in research. With current and future state requirements understood, a scenario planning exercise conducted with key senior executives led to the establishment of a strategy and 3-5 year implementation roadmap to help the research organization to realize its potential.

The results
The new research operating model, with its flexible, integrated global network of clearly defined roles and capabilities led to better alignment with therapeutic areas and a more sustainable and scalable pipeline flow. The new model has increased the probability of translating research productivity to late stage clinical success and is anticipated to contribute significant cost savings through enhanced asset utilization and expanded access to external science.

Featured insights

In the face of uncertainty - A challenging future for biopharmaceutical innovation
A recent Deloitte study has shown that the overall rate of return on R&D investment for the 12 largest biopharmaceutical firms has dropped significantly since 2010, and the cost of developing a new medicine has risen substantially. Learn more.
Health Care Reform - Redefining biopharma innovation
Learn how reform will indirectly impact biopharma through changing stakeholder relationships.
The new gold standard: Pfizer's quality by design approach to trial management
Read the Pharmaceutical Executive article.
Measuring the return from innovation: Is R&D earning its investment?
With an increasing focus on R&D ROI, how can R&D organizations better address the challenge of declining productivity while managing the expectations of their boards and the wider investor community?
R&D leadership in today's environment
As companies strive to become more efficient and seek alternative streams of revenue, they need R&D leaders who have a profound understanding of business as well as science.
Deloitte solutions Capabilities

R&D Operating Strategy

  • Global Operating Strategy and Model Development
  • Partnering and Outsourcing Strategy
  • R&D Capability Assessment and Management
  • Portfolio Governance
  • Organizational Design and Implementation
  • Resource and Capacity Planning
  • IT Partner and Sourcing Strategy

Regulatory, Safety and Clinical Operations

  • Capability Assessment and Management
  • Process Optimization
  • Metrics and Performance Management
  • Business and Technology Solution
  • Strategy, Architecture, Design and Implementation
  • Clinical, Regulatory and Safety
  • Systems Assessment, Selection and Configuration
  • Organizational Design and Implementation
  • Clinical, Regulatory and Safety Transformation Program and Project Management

Portfolio and Resource Management

  • Portfolio Evaluation and Analysis Assessment
  • PPRM Business Process Assessment
  • Future State Operating Model and Organizational Design
  • PPRM Information and Technology Capabilities Assessment
  • Enabling Technology Architecture, Design and Implementation

Quality Management

  • Quality Diagnostic & Maturity Assessment
  • Quality Management Strategy
  • Quality Standards Development
  • Performance Management & Analytics
  • Quality Risk and Compliance Management
  • Quality Management Solution Design, Development and Implementation
R&D IT Transformation
  • Emerging Technology Strategies and Pilots
  • R&D Business and IT Capability Assessments and Roadmaps
  • IT Investments Optimization
  • Technology Partner and Sourcing Strategy and Implementation
  • Technology Adoption and Migration Strategy
  • Information and Decision-based Culture Adoption
  • Information Security, Risk, Privacy and Protection

Data Analytics and Information Management

  • Health Informatics and Insights for Comparative Effectiveness
  • Translational Research and Informatics
  • Advanced Analytics: Modeling and Simulation, Visualization, Data Mining
  • Scientific and Regulatory Informatics
  • Enterprise Business Intelligence
  • Operational Reporting and Performance Management
  • Information Management Services
  • Data Warehouse / Data Mart for Consolidation of Clinical and Safety Data
  • External and Partner Data integration
  • Providers and Health Plans Clinical Data Mining


Talent Management
  • Competency modeling, talent, assessment ; training
  • Leadership development, succession planning
  • Talent and recruitment strategy
  • Performance Management
  • Change Management



Deloitte’s Life Sciences Research and Development leadership team

Ralph Marcello
Principal, Deloitte Consulting LLP
Asif Dhar
Principal, Deloitte Consulting LLP
Peter Russell
Principal, Deloitte Consulting LLP
Marc Kaplan
Principal, Deloitte Consulting LLP
Nitin Mittal
Principal, Deloitte Consulting LLP
Rich Cohen
Principal, Deloitte Consulting LLP
David Rosner
Principal, Deloitte Consulting LLP
Tracy Nielsen
Principal, Deloitte Consulting LLP
Jen Markey
Director, Deloitte Consulting LLP
  Dr. John Whitebrook
Director, Deloitte Consulting LLP
Rajeev Vasudeva
Director, Deloitte Consulting LLP
Bill Karl
Director, Deloitte Consulting LLP
Jacques Mulder
Principal, Deloitte Consulting LLP
Neil Lesser
Principal, Deloitte Consulting LLP
Steve Pratt
Principal, Deloitte Consulting LLP

As used in this document, "Deloitte" means Deloitte Consulting LLP, a subsidiary of Deloitte LLP. Please see for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

Related links

Share this page

Email this Send to LinkedIn Send to Facebook Tweet this More sharing options

Stay connected